Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 20/100

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

Key Takeaway: Corcept Therapeutics is currently facing a class action lawsuit for allegedly failing to disclose crucial information to investors related to its product candidate, relacorilant. The lawsuit claims that the company's representatives misled investors regarding the likelihood of FDA approval for relacorilant. Following the FDA's Complete Response Letter on December 31, 2025, which outlined the need for additional evidence to assess the drug's efficacy, Corcept's stock plummeted by over 50%. ClaimFiler is advising investors with losses exceeding $100,000 to file lead plaintiff applications by April 21, 2026.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept Therapeutics is facing a class action lawsuit due to allegations of failing to disclose material information during the stock's class period.
  • The company's share price dropped by over 50% following a negative FDA response regarding its lead product candidate, relacorilant.
  • Investors who incurred losses over $100,000 are being alerted about the lead plaintiff deadline, highlighting the serious financial implications of the lawsuit.

Full Press Release Details

NEW ORLEANS, April 16, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Corcept investors should visit us at https://claimsfiler.com/cases/nasdaq-cort-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s New Drug Application (“NDA”) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant and that it had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
On this news, the price of Corcept’s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.
The case is Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline for filing a lead plaintiff application?

The deadline to file lead plaintiff applications is April 21, 2026.

What allegations are made against Corcept Therapeutics?

Corcept is accused of failing to disclose vital information, violating federal securities laws.

Why did Corcept's stock price drop significantly?

The stock plummeted after the FDA issued a Complete Response Letter for relacorilant.

How can Corcept investors seek legal help?

Investors can contact ClaimsFiler at 844-367-9658 or visit their website for assistance.

What is the class period for this lawsuit?

The class period for the lawsuit runs from October 31, 2024, to December 30, 2025.

Last updated: Apr 16, 2026